4 chapters across the catalog
Actor Billy Porter's public announcement of his HIV status is discussed alongside his participation in a 2019 Johnson & Johnson commercial for an exploratory HIV vaccine. The hosts criticize the use of celebrities to "shill" for pharmaceutical companies. The segment notes that clinical trials for these vaccines were conducted in Africa before moving to other regions.
Medical researchers suggest that future vaccine dosages may be determined by genetic markers rather than race, potentially requiring different doses for different ethnic groups. There is a critical perspective offered that minority populations are often used as the "baseline" for testing new medical technologies before they are calibrated for wealthier populations. This practice is framed as a form of systemic racism within the pharmaceutical industry.
Historical medical abuses like the Tuskegee experiment contribute to a deep-seated mistrust of vaccines within the black community, with polls showing only 25% willingness to participate. Anecdotes about individuals living off medical trial stipends illustrate the economic desperation often tied to testing. This skepticism extends to high-risk demographics who refuse the vaccine despite official health recommendations.
The science behind the placebo effect is examined, noting that the name is Latin for "I shall please." Federal law requires new drugs to outperform placebos in clinical trials, which is often difficult because the mere anticipation of healing can trigger actual physiological immune responses and lower stress hormones in the body.
